WINTON GROUP Ltd Takes Position in Trevi Therapeutics, Inc. $TRVI

Posted by Geri Gentry on Sep 12th, 2026

WINTON GROUP Ltd acquired a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund acquired 106,852 shares of the company’s stock, valued at approximately $1,993,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its stake in Trevi Therapeutics by 20.4% in the 1st quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock worth $174,000 after purchasing an additional 4,688 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Trevi Therapeutics by 31.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company’s stock valued at $278,000 after buying an additional 10,445 shares during the period. Millennium Management LLC lifted its holdings in shares of Trevi Therapeutics by 356.3% in the first quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock worth $5,178,000 after buying an additional 642,830 shares in the last quarter. Strs Ohio purchased a new stake in shares of Trevi Therapeutics in the first quarter worth about $52,000. Finally, Creative Planning boosted its position in shares of Trevi Therapeutics by 17.5% in the second quarter. Creative Planning now owns 20,247 shares of the company’s stock valued at $111,000 after acquiring an additional 3,016 shares during the period. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Trading Down 0.1%

Shares of NASDAQ TRVI opened at $15.90 on Friday. Trevi Therapeutics, Inc. has a 12 month low of $7.64 and a 12 month high of $20.22. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of -46.76 and a beta of 1.04. The business has a 50-day moving average of $17.80 and a 200-day moving average of $15.19.

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). On average, analysts predict that Trevi Therapeutics, Inc. will post -0.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TRVI has been the subject of several recent analyst reports. HC Wainwright boosted their price objective on shares of Trevi Therapeutics from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Wall Street Zen downgraded shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Friday, July 17th. B. Riley Financial upped their price target on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Finally, Cantor Fitzgerald increased their price objective on Trevi Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Trevi Therapeutics presently has an average rating of “Buy” and a consensus target price of $27.08.

Get Our Latest Research Report on TRVI

About Trevi Therapeutics

(Free Report)

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic cough and other conditions involving dysregulated sensory nerve activity. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine designed to reduce chronic cough through activity at opioid receptors.

Trevi is studying Haduvio for chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, as well as refractory chronic cough, a condition in which coughing persists despite treatment of underlying causes.